Pharmacotherapies for sleep disturbances in Alzheimer's disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 3, 2014, Pages

  Mccleery, Jenny ^a   Cohen, Daniel A ^b   Sharpley, Ann L ^c  

^a OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; RAMELTEON; TRAZODONE; INDENE DERIVATIVE;

ACTIMETRY; ALZHEIMER DISEASE; CIRCADIAN RHYTHM SLEEP DISORDER; DAILY LIFE ACTIVITY; DAYTIME SOMNOLENCE; DECISION MAKING; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HOSPITAL ADMISSION; HUMAN; HYPERSOMNIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; NIGHT SLEEP; PARASOMNIA; PEER REVIEW; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; DRUG EFFECT; META ANALYSIS; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLEEP; SLEEP DISORDER;

ALZHEIMER DISEASE; HUMANS; INDENES; MELATONIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SLEEP; SLEEP DISORDERS; TRAZODONE;

EID: 84907424429     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009178.pub2     Document Type: Review

References (73)

1. Trazodone for the treatment of sleep disorders in Alzheimer's disease: a randomised, double-blind, placebo-controlled study. ClinicalTrials.gov.
2. Camargos EF, Louzada LL, Quintas JL, Naves JOS, Louzada FM, Nobrega OT. Trazodone inproves sleep parameters in Alzheimer disease patients: a randomized, double-blind and placebo-controlled study. American Journal of Geriatric Psychiatry 2014:10.1016/j.jagp.2013.12.174.
3. Dowling GA, Burr RL, Van Someren EJW, Hubbard EM, Luxenberg JS, Mastick J, et al.Melatonin and bright light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease. American Journal of Geriatric Psychiatry 2008;56:239-46.
4. A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8 week treatment of Rozerem 8 mg (QHS) in sleep disturbed, mild to moderately severe Alzheimer's disease subjects. Clinicaltrials.gov.
5. Clinical Trial Synopsis 01-05-TL-375-061, NCT#00325728: A double-blind, randomized, placebo-controlled study of the efficacy, safety and tolerability of 8 week treatment of Rozerem 8 mg (QHS) in sleep disturbed, mild to moderately severe Alzheimer's disease subjects. http://www.takeda.com/research/ct/pdf/report/15_Ramelteon_01-05-TL-375-061_ClinicalTrialSynopsis_NCT00325728_en.pdf.
6. Serfaty M, Kennell-Webb S, Warner J, Blizard R, Raven P. Double blind randomised placebo controlled trial of low dose melatonin for sleep disorders in dementia. International Journal of Geriatric Psychiatry 2002;17:1120-7.
7. Singer C, Tractenberg RE, Kaye, J, Schafer K, Gamst A, Grundman M, et al.A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003;26:893-901.
8. Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. Journal of Nippon Medical School 2003;70:334-41.
9. Bergener M, Undeutsch D. Methods and problems of clinical psychopharmacology. Results of a double blind study with Medazepam and placebo in geriatric psychiatry. Arzneimittel-Forschung 1968;18:1563-6.
10. Bergonzi P, Capocchi G, Chiurulla C, Mennuni G, Tempsta E. Tryptophan and sleep in subjects with neuropsychiatric syndromes. Rivista di Neurologia 1973;43:403-9.
11. Cohen-Mansfield J, Garfinkel D, Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Archives of Gerontology and Geriatrics 2000;31:65-76.
12. Eeles E. The effect of melatonin on sleep pattern and levels of agitation in patients with dementia. National Research Register 2003.
13. Gehrmann PR, Donald JC, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S. Melatonin fails to improve sleep or agitation in a double-blind randomized placebo-controlled trial of instituitionalized patients with Alzheinmer's disease. American Journal of Geriatric Psychiatry 2009;17(2):166-9.
14. GIllman PK. Tacrine for treatment of sleep disturbance in dementia. Journal of the American Geriatrics Society 1997;45:1286.
15. Ginsburg R, Weintraub M. Caffeine in the 'Sundown syndrome'. Report of negative results. Journal of Gerontology 1976;31:419-20.
16. Haworth J. A pilot, double-blind, placebo controlled, parallel group study of the effect of melatonin treatment in patients with Alzheimer's disease and sleep. National Research Register Archive 2001.
17. Howcroft DJ, Jones RW. Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia?. International Journal of Geriatric Psychiatry 2005;20:492-5.
18. Investigation on the effects of memantine on psychiatric symptoms and sleep disturbances in patients with Alzheimer's disease. JPRN register.
19. Kittur S, Hause P. Improvement of sleep and behavior by methylphenidate in Alzheimer's disease. American Journal of Psychiatry 1999;156:1116-7.
20. Linnoila M, Viukari M, Numminen A, Auvinen J. Efficacy and side effects of chloral hydrate and tryptophan as sleeping aids in psychogeriatric patients. International Pharmacopsychiatry 1980;15:124-8.
21. Linnoila M, Viukari M, Lamminsivu U, Auvinen J. Efficacy and side effects of lorazepam, oxazepam, and temazepam as sleeping aids in psychogeriatric in-patients. International Pharmacopsychiatry 1980;15:129-35.
22. Magnus RV. A controlled trial of chlormethiazole in the management of symptoms of the organic dementias in the elderly. Clinical Therapeutics 1978;1(6).
23. Mahlberg R, Kunz D, Sutej I, Kuhl KP, Hellweg R . Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease:an open-label pilot study using actigraphy. Journal of Clinical Psychopharmacology 2004;24:456-9.
24. Markowitz JS, Gutterman EM, Lilienfeld S, Papadopoulos G. Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. Sleep 2003;26:602-6.
25. Meguro K, Meguro M, Tanaka Y, Akanuma K, Yamaguchi K, Itoh M. Risperidone is effective for wandering and disturbed sleep/wake patterns in Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 2004;17:61-7.
26. Mishima K, Okawa M, Hishikawa Y. Effect of methylcobalamin (VB12) injection on sleep-wake rhythm in demented patients. Japanese Journal of Psychiatry & Neurology 1992;46:227-8.
27. Moraes WA, Poyares DL, Ramos LR, Bertolucci PH, Tufik S. Six-month donepezil treatment alters REM sleep parameters in Alzheimer's disease patients: a double-blind placebo controlled study. Sleep 2003;26:A351.
28. Moraes WA, Poyares DR, Guilleminault C, Ramos LR, Ferreira Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep 2006;29:199-205.
29. A study of the effects on sleep, attention, and gastrointestinal tolerance of galantamine and donepezil in patients with Alzheimer's disease. ClinicalTrials.gov.
30. The effect of anticholinesterase drugs on sleep in Alzheimer's disease patients. ClinicalTrials.gov.
31. Modafinil treatment for sleep/wake disturbances in older adults. ClinicalTrials.gov.
32. Safety and feasibility of sodium oxybate in mild Alzheimer's disease patients. ClinicalTrials.gov.
33. Efficacy of Circadin® 2 mg in patients with mild to moderate Alzheimer disease treated with AChE inhibitor. ClinicalTrials.gov.
34. A study of the safety and tolerability of AZD5213 effect on sleep for patients with Alzheimer's/cognitive impairment. ClinicalTrials.gov.
35. Petit G, Montplaisir J, Lorrain D, Gauthier S. THA does not affect sleep or EEG spectral power in Alzheimer's disease. Biological Psychiatry 1993;33:753-4.
36. Riemersma-van Der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJG, Van Someren EJW. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA 2008;299:2642-55.
37. Riley McCarten J, Kovera C, Maddox MK, Cleary JP. Triazolam in Alzheimer's disease: pilot study on sleep and memory effects. Pharmacology, Biochemistry and Behavior 1995;52:447-52.
38. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. Journal of the American Geriatrics Society 2004;52:1737-43.
39. Schubert DS. Hydroxyzine for acute treatment of agitation and insomnia in organic mental disorder. Psychiatric Journal of the University of Ottawa 1984;9:59-60.
40. Scripnikov A, Khomenko A, Napryeyenko O. Effects of Ginkgo biloba extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wiener Medizinische Wochenschrift 2004;157:295-300.
41. Shaw SH, Curson H, Coquelin JP. A double-blind, comparative study of zolpidem and placebo in the treatment of insomnia in elderly psychiatric in-patients. Journal of International Medical Research 1992;20:150-61.
42. Shinno H, Inami Y, Inagaki T, Nakamura Y, Horiguchi J . Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia. Progress in Neuro-Psychopharmacology&Biological Psychiatry 2008;32:881-5.
43. Simon Padilla OJ, De Linares Del Rio C, Godden P, Granizo E, Pinilla M, Rodriguez C. Use of combined treatment with melatonin and clomethiazole in circadian rhythm sleep disorder in the elderly with dementia. Revista Espanola de Geriatria y Gerontologia 2009;44:233-4.
44. Singer CM, Nanda F. Modafinil vs. placebo: effects on daytime sleep in Alzheimer's disease. Biological Psychiatry 2007;61:144S.
45. Stahl SM, Markowitz JS, Papadopoulos G, Sadik K. Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. Current Medical Research and Opinion 2004;20:517-25.
46. Tozawa T, Mishima K, Satoh K, Matsumoto Y, Echizenya M, Sasaki M, et al . Melatonin replacement therapy for rest-activity rhythm disorders in patients with senile dementia of Alzheimer's type. Proceedings of the21st Collegium Internationale Neuropsychopharmacologium('CINP)Congress, Jul12-161998, Glasgow, Scotland. 1998.
47. Valtonen M, Niskanen L, Kangas A-P, Koskinen T. Effects of melatonin-rich night-time milk on sleep and activity in elderly institutionalized subjects. Nordic Journal of Psychiatry 2005;59:217-21.
48. Walther S, Shüpbach B, Seifritz E, Strik W. Randomized, controlled, crossover trial of dronabinol, 2.5mg, for agitation in 2 patients with dementia. Journal of Clinical Psychopharmacology 31(2): 254-6 2011.
49. Yehuda S, Rabinovtz S, Carasso RL, Mostofsky DI. Essential fatty acids preparation (sr-3) improves alzheimer's patients quality of life. International Journal of Neuroscience 1996;87:141-9.
50. A double-blind, parallel group, randomized, placebo controlled study of the efficacy of Circadin® 2mg in alleviating sleep disturbances in patients with mild to moderate Alzheimer Disease (AD) treated with Acetylcholinesterase (AChE) inhibitor.. EUCTR.
51. Zolpidem CR and hospitalized patients with dementia. ClinicalTrials.gov.
52. Ancoli-Israel S, Clopton P, Klauber MR, Fell R, Mason W. Use of wrist actigraphy for monitoring sleep/wake in demented nursing home patients. Sleep 1997;20:24-7.
53. Bliwise DL. Sleep disorders in Alzheimer's disease and other dementias. Clinical Cornerstone 2004;6 Suppl 1A:16-28.
54. Buxton OM, Copinschi G, Van Onderbergen A, Karrison TG, Van Cauter E. A benzodiazepine hypnotic facilitates adaptation of circadian rhythms and sleep-wake homeostasis to an eight hour delay shift simulating westward jet lag. Sleep 2000;23:915-27.
55. Camargos EF, Louzarda FM, Nobrega OT. Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness and challenges. Sleep Medicine Reviews 2013;17:475-88.
56. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Current Neuropharmacology 2010;8:218-27.
57. Closser MH. Benzodiazepines and the elderly: a review of potential problems. Journal of Substance Abuse Treatment 1991;8:35-41.
58. Coupland CA, Dhiman P, Barton G, Morriss R, Arthur A, Sach T, et al.A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technology Assessment 2011;15(28):1-202.
59. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003;17:825-37.
60. Deschenes CL, McCurry SM. Current treatments for sleep disturbances in individuals with dementia. Current Psychiatry Reports 2009;11:20-6.
61. Dauvilliers Y. Insomnia in patients with neurodegenerative conditions. Sleep Medicine 2007;4 Suppl:27-34.
62. David R, Zeitzer J, Friedman L, Noda A, O'Hara R, Robert P, et al.Non-pharmacologic management of sleep disturbance in Alzheimer's disease. The Journal of Nutrition, Health & Aging 2010;14:203-6.
63. Donaldson C, Tarrier N, Burns A. Determinants of carer stress in Alzheimer's disease. International Journal of Geriatric Psychiatry 1998;13:248-56.
64. Gaugler JE, Edwards AB, Femia EE, Zarit SH, Parris Stevens M-A, Townsend A, et al.Predictors of institutionalization of cognitively impaired elders: family help and the timing of placement. The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences 2000;55:247-55.
65. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
66. Mishima K, Okawa M, Hozumi S, Hishikawa Y. Supplementary administration of artificial bright light and melatonin as potent treatment for disorganized circadian rest-activity and dysfunctional autonomic and neuroendocrine systems in institutionalzed demented elderly persons. Chronobiology International 2000;17(3):419-32.
67. Montplaisir J, Petit D, Lorrain D, Gauthier S, Nielsen T. Sleep in Alzheimer's disease: further considerations on the role of brainstem and forebrain cholinergic populations in sleep-wake mechanisms. Sleep 1995;18:145-8.
68. Montplaisir J, Petit D, Gauthier S, Gaudreau H, Decary A. Sleep disturbances and eeg slowing in alzheimer's disease. Sleep Research Online 1998;1(4):147-51.
69. Oderda LH, Young JR, Asche CV, Pepper GA. Psychotropic-related hip fractures: meta-analysis of first-generation and second-generation antidepressant and antipsychotic drugs. Annals of Pharmacotherapy 2012;46:917-28.
70. Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Research 1985;342:37-44.
71. van Someren EJW. Circadian rhythms and sleep in human aging. Chronobiology International 2000;17:233-43.
72. Vitiello MV, Poceta JS, Prinz PN. Sleep in Alzheimer's disease and other dementing disorders. Canadian Journal of Psychology 1991;45:221-39.
73. Vitiello M, Bliwise D, Prinz P. Sleep in Alzheimer's disease and the sundown syndrome. Neurology 1992;42 Suppl 6:83-94.